Dr Reddy's Laboratories announced that it has launched Paricalcitol Capsules, 1 mcg, 2 mcg and 4 mcg, a therapeutic equivalent generic version of Zemplar (Paricalcitol) Capsules in the US market, following the approval by the United States Food & Drug Administration (USFDA).
The Zemplar brand and generic had US sales of approximately USD 109.6 million MAT for the most recent twelve months ending in March 2014 according to IMS Health.
Dr Reddy's Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg are available in bottle counts of 30.